^
    4d
    Identification of TXNIP, FTCD, and HAGH as Key Genes in a Cancer Stem Cell-Driven Prognostic Model for Hepatocellular Carcinoma. (PubMed, Endocr Metab Immune Disord Drug Targets)
    Potential prognostic and targeted therapy biomarkers were identified. The CSC-related module-based prognostic model may offer a new tool for personalized HCC treatment.
    Journal
    |
    TXNIP (Thioredoxin Interacting Protein)
    |
    vinorelbine tartrate
    5d
    Second primary driver-negative lung adenocarcinoma following breast cancer treatment: a case report. (PubMed, Pan Afr Med J)
    We present the case of a 60-year-old non-smoking woman previously treated for luminal B human epidermal growth factor receptor 2 (HER2)-positive invasive breast carcinoma with surgery, AC60 chemotherapy, trastuzumab, breast radiotherapy, and hormone therapy at the Mohammed VI Oncology Center in Casablanca, Morocco. The patient received neoadjuvant vinorelbine-cisplatin chemotherapy followed by volumetric modulated arc therapy (VMAT) thoracic radiotherapy at 66 Gy, achieving clinical and radiological stabilization. This case highlights the occurrence of a second driver-negative primary lung adenocarcinoma in a non-smoker and underscores the importance of integrated histopathological, immunohisto chemical, and targeted molecular evaluation in distinguishing primary tumors from metastases, as well as the potential role of post-therapeutic carcinogenesis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • RET fusion • ALK rearrangement • MET exon 14 mutation • ROS1 fusion • ROS1 rearrangement • EGFR positive
    |
    Herceptin (trastuzumab) • cisplatin • vinorelbine tartrate
    16d
    First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. (PubMed, ESMO Open)
    PADMA is the first randomized multicenter study to show that palbociclib + ET as first-line treatment compared with CT also leads to improvements in TTF and PFS in predominantly postmenopausal patients with HR-positive/HER2-negative mBC.
    Clinical • P4 data • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation
    |
    Ibrance (palbociclib) • paclitaxel • capecitabine • epirubicin • vinorelbine tartrate
    18d
    Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization. (PubMed, Curr Cancer Drug Targets)
    Six prognostic genes, particularly RAB25 and PLAU, influence ESCC progression and immune microenvironment remodeling.
    Journal
    |
    SERPINH1 (Serpin family H member 1) • MAGEA4 (Melanoma antigen family A, 4) • ANO1 (Anoctamin 1) • COL2A1 (Collagen Type II Alpha 1 Chain) • PLAU (Plasminogen Activator) • RAB25 (RAB25, Member RAS Oncogene Family)
    |
    cisplatin • docetaxel • vinorelbine tartrate
    1m
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    1m
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
    1m
    The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study. (PubMed, Transl Breast Cancer Res)
    Treatment interruption, modification, or discontinuation due to treatment-related AEs was uncommon (12.1%). Metronomic vinorelbine plus anlotinib shows favorable efficacy in HER2- advanced breast cancer without increasing the risk of AEs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • vinorelbine tartrate
    1m
    Histology-Based Induction Chemoradiotherapy Followed by Surgery for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Prospective Observational Study. (PubMed, Ann Thorac Cardiovasc Surg)
    Histology-based induction CRT followed by surgery demonstrated feasibility and favorable outcomes, particularly for Sq and EGFR-negative non-Sq NSCLC. These findings provide a reference for patients ineligible for immune checkpoint inhibitor-based therapy.
    Observational data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR negative
    |
    cisplatin • pemetrexed • vinorelbine tartrate
    1m
    Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer (clinicaltrials.gov)
    P=N/A, N=45, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • vinorelbine tartrate
    2ms
    Orbital alveolar rhabdomyosarcoma with central nervous system invasion in adult: A case report. (PubMed, Surg Neurol Int)
    The patient received adjuvant radiotherapy and chemotherapy with irinotecan, vincristine, actinomycin D, ifosfamide, cyclophosphamide, and vinorelbine. The lack of guidelines for the adult population implies the need to adapt therapeutic strategies from pediatric protocols. Comprehensive diagnosis integrating imaging, histopathology, and molecular testing is essential for accurate classification and treatment planning.
    Journal
    |
    PAX3 (Paired Box 3)
    |
    cyclophosphamide • ifosfamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin
    2ms
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=30, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate
    2ms
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc.
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • eribulin mesylate • vinorelbine tartrate • evorpacept (ALX148)